Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Eye, Ear & Vision

A Pilot Study Evaluating the Effects of 670 nm Photobiomodulation in Healthy Ageing and Age-Related Macular Degeneration

In eyes with intermediate AMD, there was no significant improvement in any functional or structural changes at any time point up to 12 months although the compliance was good.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors studied daily 670 nm red light treatment over 12 months in 31 people with intermediate age-related macular degeneration and 11 people aged 55 or older with normal retinas. Among people with normal retinas, scotopic thresholds improved by 1.77 dB, while the authors report no significant functional or structural improvement in the intermediate AMD group. The authors conclude the treatment had no effect in patients who had already progressed to intermediate AMD.

Who or what was studied
31 patients with intermediate age-related macular degeneration and 11 people aged 55 years or above with normal retina; 5 withdrew consent and 2 developed neovascular AMD and were excluded from further treatment and analysis
Wavelengths
670 nm
Limits stated in the abstract
This is a pilot study with a small sample, and the abstract reports withdrawals and exclusions during follow-up.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Limited evidence suggests that the application of 670 nm of red light alters the course of aged decline. A previous report on 18 patients showed regression of drusen and improvement in visual functions in patients with intermediate age-related macular degeneration (AMD) by 12 months. We evaluated the functional and structural effects of applying 670 nm light to 31 patients with intermediate AMD and 11 people aged 55 years or above with normal retina. The study eyes were treated daily in the morning with a 670 nm hand-held light source housed in a torch-like tube that emitted energy equivalent to 40 mW/cm2 or 4.8J/ cm2 for 2 min at the viewing aperture. Visual function in terms of best-corrected visual acuity, low luminance visual acuity, scotopic thresholds and rod-intercept time were compared between baseline and 1, 3, 6 and 12 months. Structural changes on optical coherence tomography OCT and colour photographs were also assessed. Five withdrew consent voluntarily due to the intensity of the study visit assessments and two developed neovascular AMD and were excluded from further treatment and the analysis. In normal ageing, there was an improvement in scotopic thresholds in the group with no AMD by 1.77dB (p = 0.03) and no other parameters showed any clinically significant change. In eyes with intermediate AMD, there was no significant improvement in any functional or structural changes at any time point up to 12 months although the compliance was good. This pilot study shows that photobiomodulation with 670 nm has no effect in patients who have already progressed to intermediate AMD.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

Light parameters mentioned

Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.

Wavelength
670 nm
Energy density (fluence)
4.8J/ cm2
Power density (irradiance)
40 mW/cm2

How to read a single study: what to check before relying on this kind of research.

Terms in this paper: Age-related macular degeneration, Photobiomodulation, Pilot study, Retina. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies